Business Information
The group's principal activity is to develop medicines for serious diseases from genomics and natural products. The research and development efforts of the group are focused on anti-angiogenesis, respiratory diseases, obesity, and infectious diseases. The products of the group include squalamine, which is the lead product candidate in anti-angiogenesis. Trodulamine, formerly known as produlestan, is the group's second natural aminosterol product. The group has maintained a respiratory product development program designed to discover and develop treatment alternatives for respiratory diseases.
|
|
Name |
Title
|
Email
|
| Zola Horovitz | Chmn. | N/A | | Leanne Kelly | CFO, Sr. VP, Sec. | N/A | | Henry Wolfe | Sr. VP - Business Development and Research & Development | Available | | John Skolas | CFO, Exec. VP, General Counsel, Sec. | N/A | | Michael Gast | Exec. VP - Clinical Research, Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 892 | (21,234) | | 2005 | 446 | (26,361) | | 2004 | 873 | (17,873)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
